 | • レポートコード：QYR2104Z1458 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、併用抗体療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法/抗体、抗体/抗体、結合抗体、二重特異性抗体）、用途別市場規模（病院、がん研究所、クリニック、ASC）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・併用抗体療法の市場動向 ・企業の競争状況、市場シェア ・併用抗体療法の種類別市場規模（化学療法/抗体、抗体/抗体、結合抗体、二重特異性抗体） ・併用抗体療法の用途別市場規模（病院、がん研究所、クリニック、ASC） ・併用抗体療法の北米市場規模2016-2027（アメリカ、カナダ） ・併用抗体療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・併用抗体療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・併用抗体療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・併用抗体療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Biogen、Roche Holdings、Seattle Genetics、Amgen、Bristol-Myers Squibb、Eli Lilly、Novartis、Sanofi、Celgene、Genmab） ・結論 |
Combination antibody therapy is receiving higher recognition from the oncological branch of medical science research. This is primarily due to the growing use of combination therapy over single drug treatments such as radiation or chemotherapy. In addition, companies that manufacture combination antibody drugs are actively focusing on developing superior drugs that will deliver standout results. Factors such as encouraging government policies, growing concerns over higher cancer prevalence worldwide, and increasing research and development activities coupled with heavier investments are expected to boost the overall market growth in the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings and also propelling the growth of global combination antibody therapy market to a significant extent.
The first and foremost reason for fueling the growth of the chemotherapy/antibody segment is the rise in the rates of cancer across the globe. Cancer is the second leading cause of death globally after cardiovascular disease. The proportion of deaths around the world due to cancer has increased remarkably in the last few years.
Market Analysis and Insights: Global Combination Antibody Therapy Market
The global Combination Antibody Therapy market size is projected to reach US$ 59010 million by 2026, from US$ 34240 million in 2019, at a CAGR of 8.0% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Combination Antibody Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Combination Antibody Therapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Combination Antibody Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Combination Antibody Therapy market.
Global Combination Antibody Therapy Scope and Market Size
Combination Antibody Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Combination Antibody Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Chemotherapy/Antibody
Antibody/Antibody
Conjugated Antibodies
Bispecific Antibodies
Segment by Application
Hospitals
Cancer Research Institutes
Clinics
ASCs
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Biogen
Roche Holdings
Seattle Genetics
Amgen
Bristol-Myers Squibb
Eli Lilly
Novartis
Sanofi
Celgene
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Combination Antibody Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy/Antibody
1.2.3 Antibody/Antibody
1.2.4 Conjugated Antibodies
1.2.5 Bispecific Antibodies
1.3 Market by Application
1.3.1 Global Combination Antibody Therapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Research Institutes
1.3.4 Clinics
1.3.5 ASCs
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Combination Antibody Therapy Market Perspective (2016-2027)
2.2 Combination Antibody Therapy Growth Trends by Regions
2.2.1 Combination Antibody Therapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Combination Antibody Therapy Historic Market Share by Regions (2016-2021)
2.2.3 Combination Antibody Therapy Forecasted Market Size by Regions (2022-2027)
2.3 Combination Antibody Therapy Industry Dynamic
2.3.1 Combination Antibody Therapy Market Trends
2.3.2 Combination Antibody Therapy Market Drivers
2.3.3 Combination Antibody Therapy Market Challenges
2.3.4 Combination Antibody Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Combination Antibody Therapy Players by Revenue
3.1.1 Global Top Combination Antibody Therapy Players by Revenue (2016-2021)
3.1.2 Global Combination Antibody Therapy Revenue Market Share by Players (2016-2021)
3.2 Global Combination Antibody Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Combination Antibody Therapy Revenue
3.4 Global Combination Antibody Therapy Market Concentration Ratio
3.4.1 Global Combination Antibody Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Combination Antibody Therapy Revenue in 2020
3.5 Combination Antibody Therapy Key Players Head office and Area Served
3.6 Key Players Combination Antibody Therapy Product Solution and Service
3.7 Date of Enter into Combination Antibody Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Combination Antibody Therapy Breakdown Data by Type
4.1 Global Combination Antibody Therapy Historic Market Size by Type (2016-2021)
4.2 Global Combination Antibody Therapy Forecasted Market Size by Type (2022-2027)
5 Combination Antibody Therapy Breakdown Data by Application
5.1 Global Combination Antibody Therapy Historic Market Size by Application (2016-2021)
5.2 Global Combination Antibody Therapy Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Combination Antibody Therapy Market Size (2016-2027)
6.2 North America Combination Antibody Therapy Market Size by Type
6.2.1 North America Combination Antibody Therapy Market Size by Type (2016-2021)
6.2.2 North America Combination Antibody Therapy Market Size by Type (2022-2027)
6.2.3 North America Combination Antibody Therapy Market Size by Type (2016-2027)
6.3 North America Combination Antibody Therapy Market Size by Application
6.3.1 North America Combination Antibody Therapy Market Size by Application (2016-2021)
6.3.2 North America Combination Antibody Therapy Market Size by Application (2022-2027)
6.3.3 North America Combination Antibody Therapy Market Size by Application (2016-2027)
6.4 North America Combination Antibody Therapy Market Size by Country
6.4.1 North America Combination Antibody Therapy Market Size by Country (2016-2021)
6.4.2 North America Combination Antibody Therapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Combination Antibody Therapy Market Size (2016-2027)
7.2 Europe Combination Antibody Therapy Market Size by Type
7.2.1 Europe Combination Antibody Therapy Market Size by Type (2016-2021)
7.2.2 Europe Combination Antibody Therapy Market Size by Type (2022-2027)
7.2.3 Europe Combination Antibody Therapy Market Size by Type (2016-2027)
7.3 Europe Combination Antibody Therapy Market Size by Application
7.3.1 Europe Combination Antibody Therapy Market Size by Application (2016-2021)
7.3.2 Europe Combination Antibody Therapy Market Size by Application (2022-2027)
7.3.3 Europe Combination Antibody Therapy Market Size by Application (2016-2027)
7.4 Europe Combination Antibody Therapy Market Size by Country
7.4.1 Europe Combination Antibody Therapy Market Size by Country (2016-2021)
7.4.2 Europe Combination Antibody Therapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Combination Antibody Therapy Market Size (2016-2027)
8.2 Asia-Pacific Combination Antibody Therapy Market Size by Type
8.2.1 Asia-Pacific Combination Antibody Therapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Combination Antibody Therapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Combination Antibody Therapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Combination Antibody Therapy Market Size by Application
8.3.1 Asia-Pacific Combination Antibody Therapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Combination Antibody Therapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Combination Antibody Therapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Combination Antibody Therapy Market Size by Region
8.4.1 Asia-Pacific Combination Antibody Therapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Combination Antibody Therapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Combination Antibody Therapy Market Size (2016-2027)
9.2 Latin America Combination Antibody Therapy Market Size by Type
9.2.1 Latin America Combination Antibody Therapy Market Size by Type (2016-2021)
9.2.2 Latin America Combination Antibody Therapy Market Size by Type (2022-2027)
9.2.3 Latin America Combination Antibody Therapy Market Size by Type (2016-2027)
9.3 Latin America Combination Antibody Therapy Market Size by Application
9.3.1 Latin America Combination Antibody Therapy Market Size by Application (2016-2021)
9.3.2 Latin America Combination Antibody Therapy Market Size by Application (2022-2027)
9.3.3 Latin America Combination Antibody Therapy Market Size by Application (2016-2027)
9.4 Latin America Combination Antibody Therapy Market Size by Country
9.4.1 Latin America Combination Antibody Therapy Market Size by Country (2016-2021)
9.4.2 Latin America Combination Antibody Therapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Combination Antibody Therapy Market Size (2016-2027)
10.2 Middle East & Africa Combination Antibody Therapy Market Size by Type
10.2.1 Middle East & Africa Combination Antibody Therapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Combination Antibody Therapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Combination Antibody Therapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Combination Antibody Therapy Market Size by Application
10.3.1 Middle East & Africa Combination Antibody Therapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Combination Antibody Therapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Combination Antibody Therapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Combination Antibody Therapy Market Size by Country
10.4.1 Middle East & Africa Combination Antibody Therapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Combination Antibody Therapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Combination Antibody Therapy Introduction
11.1.4 Biogen Revenue in Combination Antibody Therapy Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Roche Holdings
11.2.1 Roche Holdings Company Details
11.2.2 Roche Holdings Business Overview
11.2.3 Roche Holdings Combination Antibody Therapy Introduction
11.2.4 Roche Holdings Revenue in Combination Antibody Therapy Business (2016-2021)
11.2.5 Roche Holdings Recent Development
11.3 Seattle Genetics
11.3.1 Seattle Genetics Company Details
11.3.2 Seattle Genetics Business Overview
11.3.3 Seattle Genetics Combination Antibody Therapy Introduction
11.3.4 Seattle Genetics Revenue in Combination Antibody Therapy Business (2016-2021)
11.3.5 Seattle Genetics Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Combination Antibody Therapy Introduction
11.4.4 Amgen Revenue in Combination Antibody Therapy Business (2016-2021)
11.4.5 Amgen Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Combination Antibody Therapy Introduction
11.5.4 Bristol-Myers Squibb Revenue in Combination Antibody Therapy Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Combination Antibody Therapy Introduction
11.6.4 Eli Lilly Revenue in Combination Antibody Therapy Business (2016-2021)
11.6.5 Eli Lilly Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Combination Antibody Therapy Introduction
11.7.4 Novartis Revenue in Combination Antibody Therapy Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Combination Antibody Therapy Introduction
11.8.4 Sanofi Revenue in Combination Antibody Therapy Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 Celgene
11.9.1 Celgene Company Details
11.9.2 Celgene Business Overview
11.9.3 Celgene Combination Antibody Therapy Introduction
11.9.4 Celgene Revenue in Combination Antibody Therapy Business (2016-2021)
11.9.5 Celgene Recent Development
11.10 Genmab
11.10.1 Genmab Company Details
11.10.2 Genmab Business Overview
11.10.3 Genmab Combination Antibody Therapy Introduction
11.10.4 Genmab Revenue in Combination Antibody Therapy Business (2016-2021)
11.10.5 Genmab Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Combination Antibody Therapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy/Antibody
Table 3. Key Players of Antibody/Antibody
Table 4. Key Players of Conjugated Antibodies
Table 5. Key Players of Bispecific Antibodies
Table 6. Global Combination Antibody Therapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Combination Antibody Therapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Combination Antibody Therapy Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Combination Antibody Therapy Market Share by Regions (2016-2021)
Table 10. Global Combination Antibody Therapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Combination Antibody Therapy Market Share by Regions (2022-2027)
Table 12. Combination Antibody Therapy Market Trends
Table 13. Combination Antibody Therapy Market Drivers
Table 14. Combination Antibody Therapy Market Challenges
Table 15. Combination Antibody Therapy Market Restraints
Table 16. Global Combination Antibody Therapy Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Combination Antibody Therapy Market Share by Players (2016-2021)
Table 18. Global Top Combination Antibody Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Combination Antibody Therapy as of 2020)
Table 19. Ranking of Global Top Combination Antibody Therapy Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Combination Antibody Therapy Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Combination Antibody Therapy Product Solution and Service
Table 23. Date of Enter into Combination Antibody Therapy Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Combination Antibody Therapy Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Combination Antibody Therapy Revenue Market Share by Type (2016-2021)
Table 27. Global Combination Antibody Therapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Combination Antibody Therapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Combination Antibody Therapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Combination Antibody Therapy Revenue Market Share by Application (2016-2021)
Table 31. Global Combination Antibody Therapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Combination Antibody Therapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Combination Antibody Therapy Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Combination Antibody Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Combination Antibody Therapy Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Combination Antibody Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Combination Antibody Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Combination Antibody Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Combination Antibody Therapy Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Combination Antibody Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Combination Antibody Therapy Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Combination Antibody Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Combination Antibody Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Combination Antibody Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Combination Antibody Therapy Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Combination Antibody Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Combination Antibody Therapy Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Combination Antibody Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Combination Antibody Therapy Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Combination Antibody Therapy Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Combination Antibody Therapy Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Combination Antibody Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Combination Antibody Therapy Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Combination Antibody Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Combination Antibody Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Combination Antibody Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Combination Antibody Therapy Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Combination Antibody Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Combination Antibody Therapy Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Combination Antibody Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Combination Antibody Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Combination Antibody Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 63. Biogen Company Details
Table 64. Biogen Business Overview
Table 65. Biogen Combination Antibody Therapy Product
Table 66. Biogen Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 67. Biogen Recent Development
Table 68. Roche Holdings Company Details
Table 69. Roche Holdings Business Overview
Table 70. Roche Holdings Combination Antibody Therapy Product
Table 71. Roche Holdings Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 72. Roche Holdings Recent Development
Table 73. Seattle Genetics Company Details
Table 74. Seattle Genetics Business Overview
Table 75. Seattle Genetics Combination Antibody Therapy Product
Table 76. Seattle Genetics Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 77. Seattle Genetics Recent Development
Table 78. Amgen Company Details
Table 79. Amgen Business Overview
Table 80. Amgen Combination Antibody Therapy Product
Table 81. Amgen Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 82. Amgen Recent Development
Table 83. Bristol-Myers Squibb Company Details
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Combination Antibody Therapy Product
Table 86. Bristol-Myers Squibb Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Eli Lilly Company Details
Table 89. Eli Lilly Business Overview
Table 90. Eli Lilly Combination Antibody Therapy Product
Table 91. Eli Lilly Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 92. Eli Lilly Recent Development
Table 93. Novartis Company Details
Table 94. Novartis Business Overview
Table 95. Novartis Combination Antibody Therapy Product
Table 96. Novartis Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 101. Sanofi Recent Development
Table 102. Celgene Company Details
Table 103. Celgene Business Overview
Table 104. Celgene Combination Antibody Therapy Product
Table 105. Celgene Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 106. Celgene Recent Development
Table 107. Genmab Company Details
Table 108. Genmab Business Overview
Table 109. Genmab Combination Antibody Therapy Product
Table 110. Genmab Revenue in Combination Antibody Therapy Business (2016-2021) & (US$ Million)
Table 111. Genmab Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Combination Antibody Therapy Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy/Antibody Features
Figure 3. Antibody/Antibody Features
Figure 4. Conjugated Antibodies Features
Figure 5. Bispecific Antibodies Features
Figure 6. Global Combination Antibody Therapy Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Cancer Research Institutes Case Studies
Figure 9. Clinics Case Studies
Figure 10. ASCs Case Studies
Figure 11. Combination Antibody Therapy Report Years Considered
Figure 12. Global Combination Antibody Therapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Combination Antibody Therapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Combination Antibody Therapy Market Share by Regions: 2020 VS 2027
Figure 15. Global Combination Antibody Therapy Market Share by Regions (2022-2027)
Figure 16. Global Combination Antibody Therapy Market Share by Players in 2020
Figure 17. Global Top Combination Antibody Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Combination Antibody Therapy as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Combination Antibody Therapy Revenue in 2020
Figure 19. Global Combination Antibody Therapy Revenue Market Share by Type (2016-2021)
Figure 20. Global Combination Antibody Therapy Revenue Market Share by Type (2022-2027)
Figure 21. North America Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Combination Antibody Therapy Market Share by Type (2016-2027)
Figure 23. North America Combination Antibody Therapy Market Share by Application (2016-2027)
Figure 24. North America Combination Antibody Therapy Market Share by Country (2016-2027)
Figure 25. United States Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Combination Antibody Therapy Market Share by Type (2016-2027)
Figure 29. Europe Combination Antibody Therapy Market Share by Application (2016-2027)
Figure 30. Europe Combination Antibody Therapy Market Share by Country (2016-2027)
Figure 31. Germany Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Combination Antibody Therapy Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Combination Antibody Therapy Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Combination Antibody Therapy Market Share by Region (2016-2027)
Figure 41. China Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Combination Antibody Therapy Market Share by Type (2016-2027)
Figure 49. Latin America Combination Antibody Therapy Market Share by Application (2016-2027)
Figure 50. Latin America Combination Antibody Therapy Market Share by Country (2016-2027)
Figure 51. Mexico Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Combination Antibody Therapy Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Combination Antibody Therapy Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Combination Antibody Therapy Market Share by Country (2016-2027)
Figure 57. Turkey Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Combination Antibody Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Biogen Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 61. Roche Holdings Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 62. Seattle Genetics Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 63. Amgen Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 65. Eli Lilly Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 67. Sanofi Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 68. Celgene Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 69. Genmab Revenue Growth Rate in Combination Antibody Therapy Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
世界のモノクローナル抗体療法市場規模・現状・予測（2021年-2027年） Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal ant…- 世界のFAM20B遺伝子（XYLK抗体）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global FAM20B Gene(XYLK Antibody) Market The global FAM20B Gene(XYLK Antibody) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …
- 世界のGNSグルコサミン（GNS抗体）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global GNS Glucosamine (GNS Antibody) Market The global GNS Glucosamine (GNS Antibody) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data int…
- 世界のGNSグルコサミン（GNS抗体）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global GNS Glucosamine (GNS Antibody) Market The global GNS Glucosamine (GNS Antibody) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data int…
- 世界のEXTL1抗体市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global EXTL1 Antibody Market The global EXTL1 Antibody market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brill…